Transgene Biotek Ltd - Updates on setting-up of a new facility for biologics and their formulations - Phase I

NiedlFree Technologies Pvt Ltd has completed setting-up of Phase I of its new facilities for the development and production of biologics and novel formulations at the premises of Transgene Biotek. Transgene Biotek, as informed earlier, has a significant interest in NiedlFree Technologies Pvt Ltd.

NiedlFree Technologies having to require a regulatory compliant facility to seek relevant approvals for advancing towards clinical studies on various formulations for varied clinical applications such as Diabetes, Osteoporosis etc has invested and completed the development of Phase I of its new facilities at the premises of Transgene Biotek at IDA Bollaram, Telangana.

Shares of TRANSGENE BIOTEK LTD. was last trading in BSE at Rs. 2.57 as compared to the previous close of Rs. 2.54. The total number of shares traded during the day was 67649 in over 32 trades.

The stock hit an intraday high of Rs. 2.66 and intraday low of 2.46. The net turnover during the day was Rs. 173982.00.

Source : Equity Bulls

Keywords

TRANSGENEBIOTEK INE773D01018 NiedlFreeTechnologies Phase1 Biologics